Arsenic Trioxide (ATO III ) Induces NAD(P)H Quinone Oxidoreductase 1 (NQO1) Expression in Hepatic and Extrahepatic Tissues of C57BL/6 Mice
Chemical Research in Toxicology · 2024
DOI: 10.1021/acs.chemrestox.4c00422 ↗Kurz gefasst
Fachartikel in der Zeitschrift Chemical Research in Toxicology, 2024. Verfasst von Sara R El-Mahrouk und 3 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, Alberta T6G 2H1, Canada. Hauptthemen laut MEDLINE: NAD(P)H Dehydrogenase (Quinone), Mice, Inbred C57BL, Arsenic Trioxide, Liver. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 74 Literaturangaben. Gefördert von: Natural Sciences and Engineering Research Council of Canada, Alberta Innovates, Cancer Research Society.
Abstract (Originalsprache)
Arsenic trioxide (ATOIII) has emerged as a potent therapeutic agent for acute promyelocytic leukemia (APL), yet its clinical application is often limited by significant adverse effects. This study investigates the molecular mechanisms underlying ATOIII's impact on cellular detoxification pathways, focusing on the regulation of NAD(P)H/quinone oxidoreductase (NQO1), a crucial enzyme in maintaining cellular homeostasis and cancer prevention. We explored ATOIII's effects on NQO1 expression in C57BL/6 mice and Hepa-1c1c7 cells, both independently and in combination with 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), a known NQO1 inducer. Our findings revealed that ATOIII significantly increased NQO1 expression in hepatic and extrahepatic tissues, as well as in Hepa-1c1c7 cells, at mRNA, protein, and activity levels. This upregulation occurred both in the presence and absence of TCDD. Mechanistically, we demonstrated that ATOIII promotes the nuclear translocation of both nuclear factor erythroid 2-related factor-2 (NRF2) and aryl hydrocarbon receptor (AHR) transcription factors. Furthermore, ATOIII exposure increased antioxidant response element (ARE)-driven reporter gene activity, indicating a transcriptional mechanism of NQO1 induction. Notably, gene silencing experiments confirmed the critical roles of both NRF2 and AHR in mediating ATOIII-induced NQO1 expression. In conclusion, ATOIII exposure is found to upregulate the NQO1 enzyme through a transcriptional mechanism via AHR- and NRF2- dependent mechanisms, offering valuable insights into its therapeutic mechanisms.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, Alberta T6G 2H1, Canada.
- Faculty of Pharmacy, Tanta University, Gharbia, Tanta 31111, Egypt.
- Department of Pharmacology, College of Pharmacy, King Khalid University, Abha 61421, Saudi Arabia.
ORCID-Profile: Ayman O S El-Kadi
Förderung
- Natural Sciences and Engineering Research Council of Canada
- Alberta Innovates
- Cancer Research Society
- Leukemia and Lymphoma Society of Canada
Zitieren
APA
El-Mahrouk, S. R., El-Ghiaty, M. A., Alqahtani, M. A., & El-Kadi, A. O. S. (2024). Arsenic Trioxide (ATO III ) Induces NAD(P)H Quinone Oxidoreductase 1 (NQO1) Expression in Hepatic and Extrahepatic Tissues of C57BL/6 Mice. Chemical Research in Toxicology. https://doi.org/10.1021/acs.chemrestox.4c00422
Vancouver
El-Mahrouk SR, El-Ghiaty MA, Alqahtani MA, El-Kadi AOS. Arsenic Trioxide (ATO III ) Induces NAD(P)H Quinone Oxidoreductase 1 (NQO1) Expression in Hepatic and Extrahepatic Tissues of C57BL/6 Mice. Chemical Research in Toxicology. 2024. doi:10.1021/acs.chemrestox.4c00422
BibTeX
@article{ElMahrouk2024,
author = {El-Mahrouk, Sara R and El-Ghiaty, Mahmoud A and Alqahtani, Mohammed A and El-Kadi, Ayman O S},
title = {Arsenic Trioxide (ATO III ) Induces NAD(P)H Quinone Oxidoreductase 1 (NQO1) Expression in Hepatic and Extrahepatic Tissues of C57BL/6 Mice},
journal = {Chemical Research in Toxicology},
year = {2024},
doi = {10.1021/acs.chemrestox.4c00422}
}
EUVIMED